aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
August 09, 2023 16:00 ET
|
aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD expected to initiate in the...
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
aTyr Pharma Announces Two Abstracts for ATYR1923 Accepted for Presentation at the European Respiratory Society International Congress
August 09, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Shepherd, Smith, Edwards & Kantas Assisting Puerto Rico ERS Bondholders Collect $3 Billion in Previously Invalidated Collateral
March 20, 2019 09:17 ET
|
Shepherd Smith Edwards & Kantas LLP
HOUSTON, March 20, 2019 (GLOBE NEWSWIRE) -- Lawyers with the firm Shepherd, Smith, Edwards & Kantas, LLP (SSEK Law Firm) are assisting Employee Retirement System (ERS) bondholders gain access to...
FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017
September 05, 2017 16:05 ET
|
FibroGen, Inc.
SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...